Incyte - Delaware Business Times

Bioscience and pharmaceutical, New Castle County, News, Statewide

New conference to spotlight life sciences in Delaware

Jacob Owens March 15, 2023

A new daylong conference known as “Delaware’s DNA” will showcase Delaware’s growing life science sector, expecting to draw people from across the country.

0 Comment 245 Views

Bioscience and pharmaceutical, Health Care, New Castle County, News

Incyte signs Chinese deal for skin cream

Jacob Owens December 2, 2022

WILMINGTON – Seeking to grow its international market for a skin cream that can treat a variety of conditions from eczema to vitiligo, Incyte has signed a collaboration and license […]

0 Comment 364 Views

Bioscience and pharmaceutical, Health Care, New Castle County, News

Incyte inks trial collab with Calif. cancer firm

Jacob Owens November 7, 2022

WILMINGTON – Biopharmaceutical firm Incyte announced Monday that it has signed a clinical trial collaboration and supply agreement with a California-based firm to study the combination of their drugs in […]

0 Comment 367 Views

Bioscience and pharmaceutical, Economic Development, New Castle County, News

Incyte to buy vitiligo firm for up to $1.3B

Jacob Owens October 3, 2022

WILMINGTON – Growing Wilmington-area biopharmaceutical firm Incyte has agreed to acquire a North Carolina-based firm working on a new treatment for the skin pigmentation disorder vitiligo in a deal worth […]

0 Comment 828 Views

Bioscience and pharmaceutical, Economic Development, Health Care, New Castle County, News

Incyte wins ‘historic’ FDA approval for vitiligo drug

Jacob Owens July 19, 2022

WILMINGTON – Incyte secured on Monday the first U.S. Food & Drug Administration approval for a treatment of the skin pigmentation disorder vitiligo, demonstrating the growing strength of the biopharmaceutical […]

0 Comment 850 Views

Premier Digital Partners

© 2023 Delaware Business Times

[caption id="attachment_230201" align="aligncenter" width="333"] “Delaware’s DNA” Life Science Conference. | PHOTO COURTESY OF DELAWARE BIOSCIENCE ASSOCIATION

“Delaware’s DNA” Life Science Conference. | PHOTO COURTESY OF DELAWARE BIOSCIENCE ASSOCIATION

PHOTO COURTESY OF DELAWARE BIOSCIENCE ASSOCIATION[/caption] CLAYMONT – A new daylong conference known as “Delaware’s DNA” will showcase Delaware’s growing life science sector, expecting to draw a strong crowd from around the region and across the country. The conference organized by the industry’s trade group, the Delaware BioScience Association, will run on May 11 from 9 a.m. to 6 p.m. at The Waterfall banquet facility in Claymont. The inaugural event aims to attract several hundred regional and national biomedical researchers, business leaders, investors and policymakers to network and listen to panel discussions and expert speakers on timely industry issues. Conference headliners include Delaware Gov. John Carney, Incyte CEO Hervé Hoppenot, Biotechnology Innovation Organization (BIO) interim CEO Rachel King, Aisling Capital founder Dennis Purcell, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Director Kelvin Lee, Prelude Therapeutics CEO Kris Vaddi and Eric Kmiec, director of the Gene Editing Institute and founder of CorriXR Therapeutics. In many ways, the conference will serve as a statement of Delaware’s burgeoning sector and bringing outside attention to the First State. The association’s annual gala dinner, which the conference will replace, used to draw interest from around the region and organizers expect that interest to grow, said Michael Fleming, president of Delaware Bio. “To my knowledge, it may be the first time that Delaware has ever hosted, for any industry, a full-day conference like this,” he told Delaware Business Times. “That really is showcasing the breadth of innovation, research, new company development, and leadership in the state.” Particularly exciting is the participation of King, who can fill in attendees on the industry's national landscape, and Purcell, a leading voice in venture capital for the sector, Fleming said. A University of Delaware graduate, Purcell founded the New York City-based life sciences investment firm Aisling in 2000, and today it has $1.8 billion in committed capital. He has invested in many life sciences startups that have been acquired by major companies and served on numerous boards of growing companies. In addition to the speakers, the conference will feature startups vying for the title of “Most Promising New Company.” Companies launched within the last five years are invited to apply to be among those selected to make five-minute pitches during a full session of conference participants. All event attendees will be eligible to vote on their favorite new companies. Companies selected to participate will receive complimentary access to the conference and gain significant exposure to the most influential industry audience ever assembled in the state. Top vote winners will also be recognized with prizes and invited to share their stories at future Delaware Bio programs. Another important element of Delaware’s DNA will be poster presentations on cutting-edge science by local researchers. Throughout the conference, students and faculty from area educational and biomedical research institutions will be on hand to share and discuss their compelling work with attendees. A call for proposals for the poster presentations and most promising new company applications will be issued later this week. Delaware Bio is also preparing a smartphone app that will include a partnering tool to allow attendees to schedule and conduct one-on-one meetings with other attendees after the conference. For more info, visit delawarebio.org/page/delawares-dna.